Healthcare

Investors Try On AI-based Drug Discovery with BioXcel

Last week BioXcel Therapeutics (NASDAQ: BTAI) went public at $11. It looks like a typical biotechnology company with two drugs (BXCL501 and BXCL701) in Phase 1/2 trials for mental disorders and cancer respectively. Both drugs look fairly promising based on the data presented and we’ll get to that. But BioXcel is taking a different approach…

Keep Reading

NOVN Phase 3 Results for Acne

Since we originally published a full report on Novan (NASDAQ: NOVN) the company has been delivering good results – recent Phase 2 results for genital warts from HPV were positive and ready for the next step into Phase 3. The news sent the stock up from the $20 level to the $25 level. More importantly,…

Keep Reading

Tabula Rasa Healthcare IPO Notes

Tabula Rasa (TRHC) is a healthcare service provider with ~25% sustainable growth in recurring revenue, expanding gross margins and a model that is very likely to generate 20% EBITDA margins over the long term. As you can see from the company snapshot growth is healthy. With 16.1M shares outstanding post-IPO the market capitalization is $241M at…

Keep Reading
Cotiviti Market Opportunity

Cotivti is ugly but appealing for investors.

Healthcare claims processing is soul-crushingly complex. Recently the number of “codes” used went up 5x to over 68,000. At the same time there is tremendous cost pressure so every insurer wants to ensure claims are accurate and enforce payment policies. Cotiviti (NYSE:COTV) is one of the dominant companies in medical billing and payments space. They…

Keep Reading

Intellia NTLA Jumps on CRISPR IPO Bandwagon

In February we had the Editas (EDIT) IPO which doubled promptly in the market. The entire biotechnology world is enamored with the potential of these core gene-editing technologies. One of the companies mentioned in our note: A CRISPR view of Editas was Intellia so their offering has been much anticipated. Here’s our brief note on…

Keep Reading
Whirly lollipop on orange background.

Hutchison China Meditech is a Monster

HCM priced their IPO on the US market (NASDAQ:HCM) at $13.50. The shares already trade in London (AIM:HCM). Investors can find plenty of details in the HCM IPO roadshow slide deck but there are some major takeaways here: China will be a huge market for healthcare – per capita spending today is $322 versus over…

Keep Reading
Whirly lollipop on orange background.

Syndax IPO reboot may help the fight against cancer tumors

Syndax (SNDX) tried to go public back in June of 2014 with a different management team and less compelling story. Instead they took in capital from crossover investors, did a minor pivot and brought in a new management team to lead the company forward. The proposed terms in 2014 were 4.3M shares at a $14…

Keep Reading

Now even aspirin is a mystery?

PLx Pharma (NASDAQ: PLXP) may try to price their IPO this week. At the $18 mid-point of the proposed range the market capitalization would be about $180M. The lead underwriters are Raymond James and Maxim Group with Janney Montgomery on the cover as a co-manager. Feels like a very risky line up in this stock market.…

Keep Reading

A CRISPR view of Editas

Editas (NASDAQ:EDIT) completed their IPO this week in a difficult market and is now the first “pure play” on CRISPR. In the biotechnology field CRISPR is viewed as the Next Big Thing. Journals like the MIT Technology Review have called it “the biggest biotechnology discovery of the century.” For decades money has been poured into…

Keep Reading
Whirly lollipop on orange background.

GenSight Biologics IPO

GenSight (NASDAQ: GNST)  is smaller size biotech deal with Leerick, Evercore and Canaccord on the cover. The 4.6M shares are all primary with a $14 mid-point. It’s scheduled for tonight, November 5th. Post-IPO there will be close to 19M shares with a market capitalization of $270M. This French company has two products for treating eye disease. They target forms…

Keep Reading